The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic Review
Open accessAbstract
BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) has been implicated as a cause of hepatocellular carcinoma (HCC). We performed a systematic review of epidemiology studies to confirm the association between these disorders. METHODS: We searched PubMed for original reports published from January 1992 to December 2011 that evaluated the association between NAFLD, nonalcoholic steatohepatitis (NASH), cryptogenic cirrhosis presumed to be NASH-related, and the risk of HCC. Studies were categorized as offering potential direct evidence (eg, cohort studies) or indirect evidence (eg, case-control, cross-sectional, or case-series studies) for an association. We analyzed data from a total of 17 cohort studies (3 population based, 9 clinic based [6 limited to patients with cirrhosis], and 5 natural history), 18 case-control and cross-sectional studies, and 26 case series. RESULTS: NAFLD or NASH cohorts with few or no cases of cirrhosis cases had a minimal risk for HCC (cumulative HCC mortality of 0%-3% for study periods up to 20 y). Cohorts with NASH and cirrhosis had a consistently higher risk (cumulative incidence ranging from 2.4% over 7 y to 12.8% over 3 y). However, the risk for HCC was substantially lower in these cohorts than for cohorts with hepatitis C-related cirrhosis. Factors that increased risk among cohorts with NASH and cirrhosis could not be determined, because most studies were not sufficiently powered for multivariate analysis. CONCLUSIONS: This systematic review shows that despite several limitations, there is epidemiologic evidence to support an association between NAFLD or NASH and an increased risk of HCC; risk seems to be limited to individuals with cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A systematic review and a metaanalysis concluded that the risk estimate is likely too low to justify routine screening in MASLD without evidence of advanced fi brosis. 241”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [241]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the HCC incidence in individuals without cirrhosis is very low, ranging from 0.08 to 0.63 per 1,000 PY. 240 -244”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [241]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Thomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Williams, C. D., Stengel, J. Z., Asike, M., Torres, D. M., Shaw, J. C., Contreras, M., Landt, C. L., & Harrison, S. A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,182
Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., CARUCCI, P., Musso, A., Paolis, P. D., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,436
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2010) · Annals of Medicine · doi:10.3109/07853890.2010.518623 · Cited by 1,304
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 773
Nonalcoholic fatty liver disease burden: Australia, 2019–2030
Adams, L. A., Roberts, S. K., Strasser, S. I., Mahady, S. E., Powell, E. E., Estes, C., Razavi, H. A., & George, J. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15009 · Cited by 130
Huang, C., Yeh, M., Tsai, P., Hsieh, M., Yang, H., Hsieh, M., Yang, J., Lin, Z., Chen, S., Wang, L., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.02.022 · Cited by 129
He, X., Wu, X., Chen, R., Chen, C., Liu, X., Wu, B.-J., & Huang, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162368 · Cited by 129
Voutila, J., Reebye, V., Roberts, T. C., Protopapa, P., Andrikakou, P., Blakey, D. C., Habib, R., Huber, H. E., Sætrom, P., Rossi, J. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.018 · Cited by 128
Role of mitochondria in liver metabolic health and diseases
Morio, B., Panthu, B., Bassot, A., & Rieusset, J. (2020) · Cell Calcium · doi:10.1016/j.ceca.2020.102336 · Cited by 136
Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC
Sydor, S., Best, J., Messerschmidt, I., Manka, P., Vilchez-Vargas, R., Brodesser, S., Lucas, C., Wegehaupt, A., Wenning, C., Aßmuth, S., et al. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000131 · Cited by 127
MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges
Phoolchund, A. G. S., & Khakoo, S. I. (2024) · Cancers · doi:10.3390/cancers16020259 · Cited by 137
Rustgi, V. K., Li, Y., Gupta, K., Minacapelli, C. D., Bhurwal, A., Catalano, C., & Elsaid, M. I. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.03.021 · Cited by 125
Hu, J., Che, L., Li, L., Pilo, M. G., Cigliano, A., Ribback, S., Li, X., Latte, G., Mela, M., Evert, M., et al. (2016) · Scientific Reports · doi:10.1038/srep20484 · Cited by 123
Soto-Angona, Ó., Anmella, G., Valdés-Florido, M. J., De Uribe-Viloria, N., Carvalho, A. F., Penninx, B. W. J. H., & Berk, M. (2020) · BMC Medicine · doi:10.1186/s12916-020-01713-8 · Cited by 122
Piguet, A., Saran, U., Simillion, C., Keller, I., Terracciano, L., Reeves, H. L., & Dufour, J. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.017 · Cited by 127
Tariq, Z., Green, C., & Hodson, L. (2014) · Liver International · doi:10.1111/liv.12523 · Cited by 122
Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis
Ghetti, F. D. F., de Oliveira, D. G., de Oliveira, J. M., Ferreira, L. E. V. V. D. C., Cesar, D. E., & Moreira, A. P. B. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1524-x · Cited by 125
Alexander, J., Torbenson, M. S., Wu, T., & Yeh, M. M. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12116 · Cited by 119
Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease
Rabinowich, L., & Shibolet, O. (2015) · BioMed Research International · doi:10.1155/2015/168905 · Cited by 118
Zammit, V. A. (2013) · Biochemical Journal · doi:10.1042/bj20121689 · Cited by 115
Perumpail, R. B., Wong, R. J., Ahmed, A., & Harrison, S. A. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3821-7 · Cited by 111
Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma
Weinmann, A., Alt, Y., Koch, S., Nelles, C., Düber, C., Lang, H., Otto, G., Zimmermann, T., Marquardt, J. U., Galle, P. R., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1197-x · Cited by 111
Hepatic Notch Signaling Correlates With Insulin Resistance and Nonalcoholic Fatty Liver Disease
Valenti, L. V. C., Mendoza, R. M., Rametta, R., Maggioni, M., Kitajewski, C., Shawber, C. J., & Pajvani, U. B. (2013) · Diabetes · doi:10.2337/db13-0769 · Cited by 113
Chai, C., Rivkin, M., Berkovits, L., Simerzin, A., Zorde‐Khvalevsky, E., Rosenberg, N., Klein, S., Yaish, D., Durst, R. Y., Shpitzen, S., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.08.013 · Cited by 109
Kupffer Cells in Non-alcoholic Fatty Liver Disease: Friend or Foe?
Chen, J., Deng, X., Liu, Y., Tan, Q., Huang, G., Che, Q., Guo, J., & Su, Z. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.47143 · Cited by 118
Nonalcoholic fatty liver disease – current status and future directions
Demir, M., Lang, S., & Steffen, H. (2015) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12291 · Cited by 105
Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease
Tian, Y., Wong, V. W., Chan, H. L., & Cheng, A. S. L. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.08.010 · Cited by 108
Teng, W., Zhao, L., Yang, S., Zhang, C., Liu, M., Luo, J., Jin, J., Zhang, M., Bao, C., Li, D., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.023 · Cited by 107
Younossi, Z. M., Noureddin, M., Bernstein, D., Kwo, P. Y., Russo, M. W., Shiffman, M. L., Younes, Z. H., & Abdelmalek, M. F. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001054 · Cited by 104
Variability in Cancer Risk and Outcomes Within US Latinos by National Origin and Genetic Ancestry
Stern, M. C., Fejerman, L., Das, R., Setiawan, V. W., Cruz-Correa, M. R., Pérez‐Stable, E. J., & Figueiredo, J. C. (2016) · Current Epidemiology Reports · doi:10.1007/s40471-016-0083-7 · Cited by 101
Lade, A. G., Noon, L. A., & Friedman, S. L. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000042 · Cited by 103
Gentilucci, U. V., Carotti, S., Perrone, G., Mazzarelli, C., Galati, G., Muda, A. O., Picardi, A., & Morini, S. (2014) · Liver International · doi:10.1111/liv.12531 · Cited by 99
Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease
Sartini, A., Gitto, S., Bianchini, M., Verga, M. C., Girolamo, M. D., Bertani, A., Buono, M. D., Schepis, F., Lei, B., Maria, N. D., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0124-2 · Cited by 97
Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
Wong, C. R., Nguyen, M., & Lim, J. K. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i37.8294 · Cited by 98
Weinmann, A., Koch, S., Niederle, I. M., Schulze‐Bergkamen, H., König, J., Hoppe‐Lotichius, M., Hansen, T., Pitton, M. B., Düber, C., Otto, G., et al. (2013) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182a8a793 · Cited by 93
NAFLD and thyroid function: pathophysiological and therapeutic considerations
Hatziagelaki, E., Paschou, S. A., Schön, M., Psaltopoulou, T., & Roden, M. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.08.001 · Cited by 93
Dysregulated Fatty Acid Metabolism in Hepatocellular Carcinoma
Wang, M.-D., Han, J. S., Xing, H., Zhang, H., Li, Z., Liang, L., Li, C., Dai, S., Wu, M., Shen, F., et al. (2016) · Hepatic Oncology · doi:10.2217/hep-2016-0012 · Cited by 95
Mitochondrial Dysfunction in the Transition from NASH to HCC
Léveillé, M., & Estall, J. L. (2019) · Metabolites · doi:10.3390/metabo9100233 · Cited by 94
Bambha, K. M., Wilson, L., Ünalp, A., Loomba, R. S., Neuschwander‐Tetri, B. A., Brunt, E. M., & Bass, N. M. (2013) · Liver International · doi:10.1111/liv.12379 · Cited by 90
The Changing Landscape of Hepatocellular Carcinoma
Knudsen, E. S., Gopal, P., & Singal, A. G. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.10.028 · Cited by 90
Kumar, A., Acharya, S. K., Singh, S. P., Arora, A., Dhiman, R. K., Aggarwal, R., Anand, A. C., Bhangui, P., Chawla, Y. K., Gupta, S. D., et al. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.09.007 · Cited by 89
Nonalcoholic Fatty Liver Disease, Diabetes Mellitus and Cardiovascular Disease: Newer Data
Mavrogiannaki, A. N., & Migdalis, I. N. (2013) · International Journal of Endocrinology · doi:10.1155/2013/450639 · Cited by 87
Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis
Zenouzi, R., Weismüller, T. J., Hübener, P., Schulze, K., Bubenheim, M., Pannicke, N., Weiler–Normann, C., Lenzen, H., Manns, M. P., Lohse, A. W., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.02.008 · Cited by 86
Oda, K., Uto, H., Mawatari, S., & Ido, A. (2015) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-014-0548-5 · Cited by 85
Seko, Y., Sumida, Y., Tanaka, S., Mori, K., Taketani, H., Ishiba, H., Hara, T., Okajima, A., Umemura, A., Nishikawa, T., et al. (2016) · Hepatology Research · doi:10.1111/hepr.12840 · Cited by 85
Masarone, M., Troisi, J., Aglitti, A., Torre, P., Colucci, A., Dallio, M., Federico, A., Balsano, C., & Persico, M. (2021) · Metabolomics · doi:10.1007/s11306-020-01756-1 · Cited by 85
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma
Massoud, O. I., & Charlton, M. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.014 · Cited by 88
Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer
Walker, M., El‐Serag, H. B., Sada, Y., Mittal, S., Ying, J., Duan, Z., Richardson, P., Davila, J. A., & Kanwal, F. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13505 · Cited by 84
Role of lymphocytes in liver cancer
Mossanen, J. C., & Tacke, F. (2013) · OncoImmunology · doi:10.4161/onci.26468 · Cited by 83
Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma
Said, A., & Ghufran, A. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i6.429 · Cited by 81
Hepatocellular carcinoma: a clinical and pathological overview
Renne, S. L., Sarcognato, S., Sacchi, D., Guido, M., Roncalli, M. G., Terracciano, L., & Tommaso, L. D. (2021) · Pathologica · doi:10.32074/1591-951x-295 · Cited by 81
Ofosu, A. (2018) · Annals of Gastroenterology · doi:10.20524/aog.2018.0240 · Cited by 81
Corey, K. E., Kartoun, U., Zheng, H., & Shaw, S. Y. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3952-x · Cited by 80
Wong, D. K.-H., Cheng, S. C. Y., Mak, L., To, E. W.-P., Lo, R. C., Cheung, T. T., Seto, W., Fung, J., Man, K., Lai, C., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.06.029 · Cited by 78
Kumar, A., Acharya, S. K., Singh, S. P., Saraswat, V. A., Arora, A., Duseja, A. K., Goenka, M. K., Jain, D., Kar, P., Kumar, M., et al. (2014) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2014.04.003 · Cited by 75
Ngo, M.-H. T., Jeng, H.-Y., Kuo, Y., Nanda, J. D., Brahmadhi, A., Ling, T., Chang, T., & Huang, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041931 · Cited by 79
Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers
van Meer, S., van Erpecum, K. J., Sprengers, D., Coenraad, M. J., Klümpen, H., Jansen, P. L. M., IJzermans, J. N. M., Verheij, J., van Nieuwkerk, C. M. J., Siersema, P. D., et al. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000527 · Cited by 73
“Non alcoholic fatty liver disease and eNOS dysfunction in humans”
Persico, M., Masarone, M., Damato, A., Ambrosio, M., Federico, A., Rosato, V., Bucci, T., Carrizzo, A., & Vecchione, C. (2017) · BMC Gastroenterology · doi:10.1186/s12876-017-0592-y · Cited by 74
Should patients with NAFLD/NASH Be surveyed for HCC?
Reig, M., Gambato, M., Man, N. K., Roberts, J. P., Victor, D., Orci, L. A., & Toso, C. (2019) · Transplantation · doi:10.1097/tp.0000000000002361 · Cited by 71
Cao, D., Song, X., Che, L., Li, X.-L., Pilo, M., Vidili, G., Porcu, A., Solinas, A., Cigliano, A., Pes, G., et al. (2016) · Liver international (Print) · doi:10.1111/liv.13183 · Cited by 72
Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers
Gingold, J. A., Zhu, D., Lee, D., Kaseb, A. O., & Chen, J. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.02.006 · Cited by 72
Mechanisms behind the link between obesity and gastrointestinal cancers
Tilg, H., & Moschen, A. R. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.006 · Cited by 70
Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease
Bertot, L. C., & Adams, L. A. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1549989 · Cited by 68
Role of HSD17B13 in the liver physiology and pathophysiology
Su, W., Mao, Z., Liu, Y., Zhang, X., Zhang, W., Gustafsson, J.-Α., & Guan, Y. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.10.014 · Cited by 69
Hepatic Fibrosis and the Microenvironment: Fertile Soil for Hepatocellular Carcinoma Development
Wallace, M. C., & Friedman, S. L. (2014) · Gene Expression · doi:10.3727/105221614x13919976902057 · Cited by 69
Wells, M. M., Li, Z., Addeman, B. T., McKenzie, C. A., Mujoomdar, A., Beaton, M. D., & Bird, J. R. (2016) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2016/4930987 · Cited by 67
The contrasting roles of inflammasomes in cancer.
He, Q., Fu, Y., Tian, D., & Yan, W. (2018) · Europe PMC (PubMed Central) · Cited by 62
Wang, T., Ishikawa, T., Sasaki, M., & Chiba, T. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.822190 · Cited by 64
Steatosis and NASH in type 2 diabetes
Hu, M., Phan, F., Bourron, O., Ferré, P., & Foufelle, F. (2017) · Biochimie · doi:10.1016/j.biochi.2017.10.019 · Cited by 65
Nistal, E., de Miera, L. E. S., Ballesteros-Pomar, M. D., Sánchez‐Campos, S., García‐Mediavilla, M. V., Álvarez-Cuenllas, B., Linares, P., Olcoz, J. L., Arias, M., Lobo, J. M. G., et al. (2019) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2019.6068/2018 · Cited by 64
Knebel, C., Buhrke, T., Süßmuth, R. D., Lampen, A., Marx‐Stoelting, P., & Braeuning, A. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02445-2 · Cited by 63
Nguyen, H. T., Gu, M., Werlinger, P., Cho, J.-H., Cheng, J., & Suh, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113436 · Cited by 64
Gutiérrez‐Cuevas, J., Lucano‐Landeros, S., López-Cifuentes, D., Santos, A., & Armendáriz‐Borunda, J. (2022) · Cancers · doi:10.3390/cancers15010023 · Cited by 64
HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia
Povero, D., Chen, Y., Johnson, S. M., McMahon, C. E., Pan, M., Bao, H., Petterson, X.-M. T., Blake, E., Lauer, K. P., O’Brien, D. R., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.041 · Cited by 63
Association between bone mineral density and nonalcoholic fatty liver disease in Korean adults
Lee, S., Yun, J. M., Kim, S. H., Seo, Y., Min, H. Y., Chung, E., Bae, Y. S., Ryou, I., & Cho, B. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0528-3 · Cited by 62
Relevance of low testosterone to nonalcoholic fatty liver disease
Mody, A., White, D. L., Kanwal, F., & Garcia, J. M. (2015) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000057 · Cited by 63
Gökmen, F. Y., Ahbab, S., Ataoğlu, H. E., Türker, B. Ç., Çetin, F., Türker, F., Mamaç, R. Y., & Yenigün, M. (2016) · Clinics · doi:10.6061/clinics/2016(04)08 · Cited by 61
Motta, B. M., Masarone, M., Torre, P., & Persico, M. (2023) · Cancers · doi:10.3390/cancers15225458 · Cited by 61
NAFLD leads to liver cancer: Do we have sufficient evidence?
Duan, X., Zhang, L., Fan, J., & Qiao, L. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.033 · Cited by 60
Cold‐inducible RNA ‐binding protein promotes the development of liver cancer
Sakurai, T., Yada, N., Watanabe, T., Arizumi, T., Hagiwara, S., Ueshima, K., Nishida, N., Fujita, J., & Kudo, M. (2015) · Cancer Science · doi:10.1111/cas.12611 · Cited by 60
SIRT1 in the Development and Treatment of Hepatocellular Carcinoma
Farcas, M. F., Andrei-Alexandru, G., Gulei, D., Ionescu, C., Irimie, A., Cătană, C.-S., & Berindan‐Neagoe, I. (2019) · Frontiers in Nutrition · doi:10.3389/fnut.2019.00148 · Cited by 61
The Changing Global Epidemiology of Hepatocellular Carcinoma
Caines, A. N., Selim, R., & Salgia, R. J. (2020) · Clinics in Liver Disease · doi:10.1016/j.cld.2020.06.001 · Cited by 59
Phenotypic comparison of common mouse strains developing high-fat diet-induced hepatosteatosis
Kahle, M., Horsch, M., Fridrich, B., Seelig, A., Schultheiß, J., Leonhardt, J., Irmler, M., Beckers, J., Rathkolb, B., Wolf, E., et al. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.07.009 · Cited by 59
MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis
de Conti, A., Ortega, J. F., Tryndyak, V., Dreval, K., Moreno, F. S., Rusyn, I., Beland, F. A., & Pogribny, I. P. (2017) · Oncotarget · doi:10.18632/oncotarget.19774 · Cited by 59
Hanson, A., Wilhelmsen, D., & DiStefano, J. K. (2018) · Non-Coding RNA · doi:10.3390/ncrna4030018 · Cited by 58
Zhang, Y., Wang, H., & Xiao, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095016 · Cited by 57
Hsu, C., Wu, F., Lin, K.-H., Chen, Y., Wu, P.-C., Chen, Y., Chen, C.-S., Wang, W.-H., Mar, G.-Y., & Yu, H. (2019) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000042 · Cited by 58
Xia, H., Liu, C., Li, C.-C., Fu, M., Takahashi, S., Hu, K.-Q., Aizawa, K., Suganuma, H., Wu, G. G., Zhao, L., et al. (2018) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-18-0188 · Cited by 57
Grgurević, I., Božin, T., Mikuš, M., Kukla, M., & O’Beirne, J. P. (2021) · Cancers · doi:10.3390/cancers13225844 · Cited by 58
Sadler, E. M., Mehta, N., Bhat, M., Ghanekar, A., Greig, P., Grant, D., Yao, F. Y. K., & Sapisochin, G. (2018) · Transplantation · doi:10.1097/tp.0000000000002043 · Cited by 54
Giannini, E. G., Aglitti, A., Borzio, M., Gambato, M., Guarino, M., Iavarone, M. A., Lai, Q., Sandri, G. B. L., Melandro, F., Morisco, F., et al. (2019) · Cancers · doi:10.3390/cancers11111689 · Cited by 57
Schisandrin B: A Double‐Edged Sword in Nonalcoholic Fatty Liver Disease
Leong, P. K., & Ko, K. M. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/6171658 · Cited by 56
Zhang, T., Zhang, Y., Liu, J., Ma, Y., Ye, Q., Yan, X., & Ding, L. (2022) · Cancer & Metabolism · doi:10.1186/s40170-021-00276-3 · Cited by 56
Akie, T. E., Liu, L., Nam, M., Shi, L., & Cooper, M. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125617 · Cited by 56
Méndez‐Sánchez, N., Ridruejo, E., de Mattos, Â. A., Chávez-Tapia, N. C., Zapata, R., Paraná, R., Mastaï, R., Strauss, E., Guevara-Casallas, L. G., Daruich, J. R., et al. (2014) · Annals of Hepatology · doi:10.1016/s1665-2681(19)30919-6 · Cited by 56
Wang, X., Sommerfeld, M. R., Jahn‐Hofmann, K., Cai, B., Filliol, A., Remotti, H. E., Schwabe, R. F., Kannt, A., & Tabas, I. (2019) · Hepatology Communications · doi:10.1002/hep4.1405 · Cited by 56
Relations of Liver Fat With Prevalent and Incident Atrial Fibrillation in the Framingham Heart Study
Long, M. T., Yin, X., Larson, M. G., Ellinor, P. T., Lubitz, S. A., McManus, D. D., Magnani, J. W., Stærk, L., Ko, D., Helm, R. H., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005227 · Cited by 55
A weighty problem: metabolic perturbations and the obesity-cancer link
O’Flanagan, C. H., Bowers, L. W., & Hursting, S. D. (2015) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0022 · Cited by 55
Journal of Gastroenterology and Hepatology: Issue Information
Mahady, S., & Adams, L. A. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14270 · Cited by 32
Chimoriya, R., Piya, M. K., Simmons, D. S., Ahlenstiel, G., & Ho, V. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010095 · Cited by 53
Xu, J., Shen, J., Yuan, R., Jia, B., Zhang, Y., Wang, S., Zhang, Y., Liu, M., & Wang, T. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.796207 · Cited by 53
Liu, J., Tian, Y. E., Fu, X., Mu, C., Yao, M., Ni, Y., Liu, Y., & Li, Z. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002277 · Cited by 53
Yeh, M. M., Liu, Y., & Torbenson, M. S. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.07.018 · Cited by 53
Insulin Resistance, Obesity, and Liver Cancer
Farrell, G. C. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.07.040 · Cited by 53
Metadata
- Authors
- White, D. L., Kanwal, F., & El–Serag, H. B.
- Affiliations
- Michael E. DeBakey VA Medical Center (US)
- Corresponding author
- White, Donna L.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 10
- Issue
- 12
- Pages
- 1342-1359.e2
- ISSN
- 1542-3565 (ISSN-L)
- PMC
- PMC3501546
- OpenAlex
- W1975567145
- Cited by
- 766
- References
- 73
- Citations by year
- 2026: 16 · 2025: 26 · 2024: 39 · 2023: 49 · 2022: 61 · 2021: 71 · 2020: 68 · 2019: 64 · 2018: 76 · 2017: 73 · 2016: 54 · 2015: 58 · 2014: 54 · 2013: 56
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Clinical Gastroenterology and Hepatology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (HFP90-020, DK56338)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK56338, K24DK078154, K24 DK081736-01, K01 DK078154-03, K01DK081736, P30DK056338)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, hepatocellular carcinoma, liver cirrhosis, cryptogenic cirrhosis, cancer risk, HCC mortality
- MeSH terms
- Fatty Liver, Humans, Liver Neoplasms, Risk Assessment, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
